PURPOSE: To develop a volumetric arc therapy (VMAT)-total marrow irradiation (TMI) technique for patients with hematologic malignancies. METHODS AND MATERIALS: VMAT planning was performed for 6 patients using RapidArc technology. The planning target volume consisted of all the bones in the body from the head to the mid-femur, excluding the extremities, except for the humerus, plus a 3.0-mm margin. The organs at risk included the lungs, heart, liver, kidneys, bowels, brain, eyes, and oral cavity. The VMAT-TMI technique consisted of three plans: the head and neck, the chest, and the pelvis, each with three 330° arcs. The plans were prescribed to ensure, at a minimum, 95% planning target volume dose coverage with the prescription dose (percentage of volume receiving dose of ≥12 Gy was 95%). The treatments were delivered and verified using MapCheck and ion chamber measurements. RESULTS: The VMAT-TMI technique reported in the present study provided comparable dose distributions with respect to the fixed gantry linear accelerator intensity-modulated TMI. RapidArc planning was less subjective and easier, and, most importantly, the delivery was more efficient. RapidArc reduced the treatment delivery time to approximately 18 min from 45 min with the fixed gantry linear accelerator intensity-modulated TMI. When the prescription dose coverage was reduced to 85% from 95% and the mandible and maxillary structures were not included in the planning target volume as reported in a tomotherapy study, a considerable organ at risk dose reduction of 4.2-51% was observed. The average median dose for the lungs and lenses was reduced to 5.6 Gy from 7.2 Gy and 2.4 Gy from 4.5 Gy, respectively. CONCLUSION: The RapidArc VMAT technique improved the treatment planning, dose conformality, and, most importantly, treatment delivery efficiency. The results from our study suggest that the RapidArc VMAT technology can be expected to facilitate the clinical transition of TMI.
PURPOSE: To develop a volumetric arc therapy (VMAT)-total marrow irradiation (TMI) technique for patients with hematologic malignancies. METHODS AND MATERIALS: VMAT planning was performed for 6 patients using RapidArc technology. The planning target volume consisted of all the bones in the body from the head to the mid-femur, excluding the extremities, except for the humerus, plus a 3.0-mm margin. The organs at risk included the lungs, heart, liver, kidneys, bowels, brain, eyes, and oral cavity. The VMAT-TMI technique consisted of three plans: the head and neck, the chest, and the pelvis, each with three 330° arcs. The plans were prescribed to ensure, at a minimum, 95% planning target volume dose coverage with the prescription dose (percentage of volume receiving dose of ≥12 Gy was 95%). The treatments were delivered and verified using MapCheck and ion chamber measurements. RESULTS: The VMAT-TMI technique reported in the present study provided comparable dose distributions with respect to the fixed gantry linear accelerator intensity-modulated TMI. RapidArc planning was less subjective and easier, and, most importantly, the delivery was more efficient. RapidArc reduced the treatment delivery time to approximately 18 min from 45 min with the fixed gantry linear accelerator intensity-modulated TMI. When the prescription dose coverage was reduced to 85% from 95% and the mandible and maxillary structures were not included in the planning target volume as reported in a tomotherapy study, a considerable organ at risk dose reduction of 4.2-51% was observed. The average median dose for the lungs and lenses was reduced to 5.6 Gy from 7.2 Gy and 2.4 Gy from 4.5 Gy, respectively. CONCLUSION: The RapidArc VMAT technique improved the treatment planning, dose conformality, and, most importantly, treatment delivery efficiency. The results from our study suggest that the RapidArc VMAT technology can be expected to facilitate the clinical transition of TMI.
Authors: Anthony Stein; Joycelynne Palmer; Ni-Chun Tsai; Monzr M Al Malki; Ibrahim Aldoss; Haris Ali; Ahmed Aribi; Len Farol; Chatchada Karanes; Samer Khaled; An Liu; Margaret O'Donnell; Pablo Parker; Anna Pawlowska; Vinod Pullarkat; Eric Radany; Joseph Rosenthal; Firoozeh Sahebi; Amandeep Salhotra; James F Sanchez; Tim Schultheiss; Ricardo Spielberger; Sandra H Thomas; David Snyder; Ryotaro Nakamura; Guido Marcucci; Stephen J Forman; Jeffrey Wong Journal: Biol Blood Marrow Transplant Date: 2017-01-10 Impact factor: 5.742
Authors: Taiki Magome; Jerry Froelich; Yutaka Takahashi; Luke Arentsen; Shernan Holtan; Michael R Verneris; Keenan Brown; Akihiro Haga; Keiichi Nakagawa; Jennifer L Holter Chakrabarty; Sebastian Giebel; Jeffrey Wong; Kathryn Dusenbery; Guy Storme; Susanta K Hui Journal: Int J Radiat Oncol Biol Phys Date: 2016-07-06 Impact factor: 7.038
Authors: Darren Zuro; Srideshikan Sargur Madabushi; Jamison Brooks; Bihong T Chen; Janagama Goud; Amandeep Salhotra; Joo Y Song; Liliana Echavarria Parra; Antonio Pierini; James F Sanchez; Anthony Stein; Monzr Al Malki; Marcin Kortylewski; Jeffrey Y C Wong; Parham Alaei; Jerry Froelich; Guy Storme; Susanta K Hui Journal: Int J Radiat Oncol Biol Phys Date: 2021-06-11 Impact factor: 7.038
Authors: Dennis Stanley; Kristen McConnell; Zohaib Iqbal; Ashlyn Everett; Jonathan Dodson; Kimberly Keene; Andrew McDonald Journal: Cureus Date: 2021-06-14